# PLANNING AND EVALUATION (Core 001)

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2020 · $56,074

## Abstract

Project Summary 
The Abramson Cancer Center (ACC) has a well-established internal, Institutional, and external Planning and 
Evaluation (P&E) process that engages leaders, members, and advisors from multiple disciplines, perspectives 
and levels. The goal of this process is to guide future directions, set priorities and prioritize investments of the 
Center while, at the same time, providing ongoing mechanisms to monitor, assess and adjust research 
progress, Programs, Shared Resources, allocations, and strategies. This cohesive process is supported by 
highly integrated and effective bodies, such as the Senior Leaders, Executive Committee, Program Leaders, 
Shared Resource Advisory Committees, and the External Scientific Advisory Board (ESAB), which provides 
critical advice and feedback from experts. The Planning and Evaluation process has resulted in changes in 
Program focus, development of new Cores, changes in clinical research operations, and prioritization of 
Developmental Funds. Complementing these efforts are Programmatic, Divisional and Center-wide research 
seminars, meetings and retreats that foster new interactions and collaborations with Penn colleagues and 
external experts. Strategic planning is embedded in the ACC and Penn culture. The ACC plan of 2008-2013 
set forth the goals for this period, including accelerating the translation of basic science discoveries into 
investigator-initiated clinical trials, establishing a comprehensive molecular profiling and personalized medicine 
initiative, enhancing behavioral interventions to reduce cancer risk, and promoting translation of ACC research. 
Soon after his appointment, the Center Director, Dr. Dang, defined his vision through 2020, and charged a 
group to recommend strategies to realize the Center's goals in translational research and precision medicine. 
A defining accomplishment has been $20M from the Institution to establish innovative transdisciplinary 
programmatic efforts in translational cancer research, which are fueled by multi-year Institutional grants and 
resources in high priority areas. Rigorous internal review of Programs, Shared Resources, Developmental 
Funds, and strategic plan reviews by the ESAB ensure that the ACC continues to strive for excellence and 
adheres to NCI guidelines. The ACC responds to all ESAB recommendations and then reports on its actions. 
Taken together, the integrated P&E processes have successfully guided the growth and development of the 
ACC during the project period.

## Key facts

- **NIH application ID:** 9836821
- **Project number:** 5P30CA016520-44
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Robert H. Vonderheide
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $56,074
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9836821

## Citation

> US National Institutes of Health, RePORTER application 9836821, PLANNING AND EVALUATION (Core 001) (5P30CA016520-44). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9836821. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*